Chart: Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind
Executive Summary
One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).
You may also be interested in...
FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials